Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

When I lost weight on WW, I devoted all of my time to the program and I was successful. It was when life got hard that the ...

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023, led to a surge in demand for compounded versions of the drugs. But with tirzepatide removed from the ...

Don’t despair, though — while modern cellphones don’t come with removable batteries anymore, you can still get a replacement quite easily. The easiest way to replace your smartphone battery ...

Novo's drugs Ozempic and Wegovy are household names already, and Lilly's Mounjaro and Zepbound are close behind. For the first nine months of 2024, Novo had sales of $29.4 billion, 23% higher than ...

Lilly's newest cash cow, tirzepatide -- a therapy for type 2 diabetes and weight loss that's sold under the names Mounjaro and Zepbound -- is selling a bit slower than anticipated. Though its ...

Last week, Lilly reported that Zepbound sales came in at $1.26 billion ... that tirzepatide – also used in Lilly's diabetes drug Mounjaro – was no longer on its shortages list.